Compare RCKY & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKY | ADAG |
|---|---|---|
| Founded | 1932 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 254.4M |
| IPO Year | 1996 | 2020 |
| Metric | RCKY | ADAG |
|---|---|---|
| Price | $33.49 | $3.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $8.25 |
| AVG Volume (30 Days) | 68.7K | ★ 151.8K |
| Earning Date | 04-28-2026 | 04-01-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 94.74 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $270,408,000.00 | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $4.90 | N/A |
| P/E Ratio | $195.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.28 | $1.44 |
| 52 Week High | $48.70 | $4.75 |
| Indicator | RCKY | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 45.25 |
| Support Level | $31.86 | $3.40 |
| Resistance Level | $34.36 | $3.99 |
| Average True Range (ATR) | 2.01 | 0.28 |
| MACD | -0.57 | -0.01 |
| Stochastic Oscillator | 14.13 | 54.48 |
Rocky Brands Inc is a designer, manufacturer, and marketer of premium footwear and apparel under brands such as Muck, XTRATUF, Rocky, Durango, Georgia Boot, Lehigh, Ranger, and the licensed brand Michelin. The company operates through three segments, with the wholesale segment generating the majority of revenue through sales of footwear and accessories to sporting goods stores, outdoor specialty stores, online retailers, marine stores, independent retailers, mass merchants, retail uniform stores, and specialty safety shoe stores. The retail segment focuses on direct-to-consumer sales through e-commerce platforms and company-operated stores, while the contract manufacturing segment includes sales to the U.S. military, private label production, and sourcing arrangements for customers.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.